Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer

Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging results in first-line or second-line treatment of non-small cell lung cancer patients. Meanwhile, anti-PD-1/PD-L1 immune checkpoint dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Chaoyue, Wang, Hui, Liu, Yunru, Guo, Qiaoru, Zhang, Lingling, Li, Jiajun, Zhou, Wenmin, Yan, Yanyan, Zhou, Xinke, Zhang, Jianye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531287/
https://www.ncbi.nlm.nih.gov/pubmed/33072580
http://dx.doi.org/10.3389/fonc.2020.554313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531287/
https://www.ncbi.nlm.nih.gov/pubmed/33072580
http://dx.doi.org/10.3389/fonc.2020.554313

Ejemplares similares